Tivicay (dolutegravir) / ViiV Healthcare - LARVOL DELTA

Age-Related Variations in Clinical and Biochemical Profiles of People Living With HIV. (PubMed, AIDS Res Treat) - "This multicenter cross-sectional study included 558 PLHIV aged 10-76 years receiving ART, of whom 96.4% were on dolutegravir-based regimens...In conclusion, age-related differences were observed in renal, hepatic, and virologic abnormalities among PLHIV in Ghana. These findings support the need for age-tailored biochemical monitoring and further longitudinal studies to clarify temporal relationships between aging and organ function in PLHIV."

Journal • Fibrosis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Nephrology • Renal Disease

Exploring the Relationship Between Dolutegravir and Diabetes Using Routine Data of Patients on Anti-Retroviral Treatment in a High HIV Prevalence Setting. (PubMed, Med Res Arch) - "There was a protective relationship for developing type 2 diabetes mellitus for patients on dolutegravir-based regimens in comparison to non-dolutegravir regimens. All patients commencing antiretroviral therapy should have baseline and ongoing blood glucose monitoring as a critical component in the management of HIV."

Journal • Diabetes • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Determinants of Metabolic Syndrome in Virally Suppressed People Living with HIV: A Single-Center Comparative Analysis of Antiretroviral Regimens. (PubMed, Metabolites) - "Particularly integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF) are being connected with this issue...A marginally significant trend toward lower total cholesterol was identified in patients receiving dolutegravir/TAF compared to those on darunavir/TAF...However, due to the limited sample size and low statistical power, these findings do not prove clinical equivalence. Our results suggest that in particular tightly selected settings of well-controlled patients, traditional risk factors and lifestyle may remain the primary drivers of metabolic health, although modest drug-related effects cannot be ruled out."

Journal • Dyslipidemia • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders

Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial. (PubMed, Lancet Reg Health Southeast Asia) - "We aimed to compare the virological and metabolic outcomes after switching from TDF/FTC/EFV to TDF/3TC/DTG or TDF/FTC plus RPV. This work was supported by The Royal College of Physicians of Thailand, (to R.K.). APC fee was supported by Faculty of Tropical Medicine, Mahidol University and Mahidol University (to T.N.)."

Head-to-Head • Journal • Human Immunodeficiency Virus • Infectious Disease

Atazanavir/Ritonavir-Associated Erythema Multiforme in an HIV-1-Positive Patient. (PubMed, Cureus) - "The patient was receiving tenofovir, lamivudine, and dolutegravir; however, owing to a supply chain issue, dolutegravir was substituted with atazanavir/ritonavir. The Naranjo probability score indicated a probable adverse drug reaction. This case highlights the importance of recognizing EM as a potential adverse reaction to atazanavir and of early drug withdrawal to prevent progression to more severe cutaneous adverse reactions, including Stevens-Johnson syndrome."

Journal • Dermatology • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Steven-Johnson Syndrome

Trust, but Verify: Translating Dosing Evidence to Understudied Populations in Low- and Middle-Income Countries. (PubMed, Clin Pharmacol Ther) - "Using a metformin-dolutegravir drug interaction study and colistin pharmacokinetic study from South Africa, we illustrate how body composition and disease severity, respectively, can alter dosing assumptions. Drug development and post-registration programs should include explicit translation plans using target-population data to confirm, refine, or revise dosing recommendations in understudied target populations."

Journal

Spectrum and immunovirological determinants of tumours among people living with HIV in Uganda: A retrospective cross sectional study from a specialised HIV centre, 2017-2026. (PubMed, PLoS One) - "HIV-associated tumours in this Ugandan cohort remain predominantly malignant and are dominated by KS despite high viral suppression rates. Malignancy clusters among patients with low pre-ART CD4 counts, advanced WHO stage, and short ART duration, though these are unadjusted, hypothesis-generating comparisons rather than evidence of causal or temporal gradients. These data establish the analytic platform for a prospective HIV-oncology cohort at Mildmay Hospital and Mildmay Research Centre and inform context-appropriate cancer screening priorities."

Journal • Observational data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Sarcoma • Solid Tumor • CD4

Dolutegravir Is Associated With Lower Odds of Gestational Diabetes Compared to Other Antiretroviral Therapy Regimens Among Pregnant Women in India: A Cross-Sectional Analysis. (PubMed, J Int AIDS Soc) - "Women on dolutegravir had lower odds of GDM compared to women taking other ART, despite greater weight gain. Ongoing studies are investigating the possible anti-inflammatory mechanisms."

Journal • Diabetes • Gestational Diabetes • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus • CD4

Virologic outcomes among people living with HIV on dolutegravir-based antiretroviral therapy in Kenya, 2018-2024: a comparison retrospective longitudinal analysis. (PubMed, Lancet Reg Health Afr) - "Long-term virologic outcome data of tenofovir fumarate disoproxil-lamivudine-dolutegravir (TLD) versus tenofovir fumarate disoproxil-lamivudine-efavirenz (TLE) from resource-constrained settings remain limited...No specific funding was received for the analysis. HIV program support was provided by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017-2019. (PubMed, Open Forum Infect Dis) - "In a retrospective Nigerian cohort of 33 982 people with HIV-1 initiating or switching to tenofovir, lamivudine, and dolutegravir, virological suppression reached 80%-82% among participants with available viral load data and 63%-65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression."

Journal • Human Immunodeficiency Virus • Infectious Disease

Impact of HIV status on Tuberculosis treatment outcomes in the era of Dolutegravir-Based Antiretroviral Therapy in Azerbaijan. (ERS 2026) - "In the DTG era, TB treatment outcomes among PLHIV in Azerbaijan are favorable, with high treatment success and low mortality. However, advanced immunosuppression at TB diagnosis remains present in a proportion of patients. Strengthening early HIV diagnosis, timely ART initiation, and integrated TB/HIV care is essential to further reduce TB-related mortality."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases • Tuberculosis • CD4

RIPE for Error? Evaluating Generative AI Recommendations for Tuberculosis Treatment (ERS 2026) - " Five single-sentence prompts were submitted to engines (ChatGPT, Gemini, Claude, Copilot, Perplexity): fully sensitive pulmonary TB; isoniazid-resistant lymph node TB; fully sensitive pulmonary TB with HIV on tenofovir/emtricitabine and dolutegravir; fully sensitive TB meningitis; and pulmonary tuberculosis resistant to rifampicin and isoniazid... Generative AI reproduced first-line regimens for drug-susceptible TB, including CNS and lymph node disease, but was inconsistent for MDR-TB, with only 3/5 engines recommending appropriate pathways. AI may therefore be useful in basic scenarios but remains unreliable in MDR-TB or safety-critical scenarios."

CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Quality of life among older adults with HIV after switching to bictegravir-based three-drug or dolutegravir-based two-drug regimens. (PubMed, HIV Med) - "Among adults with HIV switching antiretroviral therapy, age ≥60 years was associated with differences in the distribution of reasons for treatment switch and with better perceived QoL, but not with differences in clinical outcomes."

HEOR • Journal • Cardiovascular • Diabetes • Dyslipidemia • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy, Safety and Pharmacokinetics of DTG With RIF (clinicaltrials.gov) - P2 | N=123 | Completed | Sponsor: The HIV Netherlands Australia Thailand Research Collaboration | Recruiting ➔ Completed | N=200 ➔ 123

Enrollment change • Trial completion • Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases • Tuberculosis

Older people living with HIV: a population with high prevalence and severity of metabolic dysfunction-associated steatotic liver disease ‒ A cross-sectional study. (PubMed, Braz J Infect Dis) - "MASLD was highly prevalent among older PLWH, with a substantial proportion presenting moderate-to-severe steatosis and significant fibrosis. Metabolic and adiposity-related factors were independently associated with hepatic steatosis, while lipodystrophy and higher ALT levels were associated with greater steatosis severity."

Journal • Observational data • Fibrosis • Hepatology • Immunology • Infectious Disease • Lipodystrophy • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • CD4

Low-Level Viremia and Its Outcomes among Individuals Living with HIV on Dolutegravir-based Therapy in Western Kenya (IDWeek 2026) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Incidence of resistance-associated mutations among people with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based regimens (IDWeek 2026) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Emerging INSTI Resistance in Children and Adolescents Living with HIV: A Systematic Review and Meta-Analysis in the Dolutegravir Era (IDWeek 2026) - No abstract available

Retrospective data • Review • Human Immunodeficiency Virus • Infectious Disease

Declining HIV-1 Drug Resistance in the Dolutegravir Era Among Children and Adolescents: A Systematic Review and Meta-Analysis of Global Temporal Trends (IDWeek 2026) - No abstract available

Retrospective data • Review • Human Immunodeficiency Virus • Infectious Disease

Metabolic Changes in Pediatric HIV Patients on Contemporary Antiretroviral Therapy: Implications for Research and Interventions. (PubMed, J Pediatric Infect Dis Soc) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents with HIV-1 in IMPAACT P1093 and IMPAACT 2019. (PubMed, J Pediatric Infect Dis Soc) - P1/2 | "Small overall increases in BAZ were observed over 1 year among pediatric participants on dolutegravir-based ART, with most participants remaining in their baseline BAZ category."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity • Pediatrics

Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of Life. (PubMed, Infect Dis Ther) - "Dolutegravir/lamivudine, dolutegravir/rilpivirine and long-acting cabotegravir/rilpivirine are the regimens studied the most, supported by randomised trials and real-world evidence. Long-acting injectable strategies may be particularly valuable for individuals who face challenges with daily oral adherence or treatment-related stigma. This narrative review summarizes current evidence on the role of oral and injectable 2DRs in key domains including innovation, flexibility, tolerability, adherence and quality of life, while discussing current limitations and future perspectives."

HEOR • Journal • Review • Human Immunodeficiency Virus • Infectious Disease

The hidden reservoir of INSTI resistance: large scale sequence analysis identifies prevalent Gag NC mutations compromising dolutegravir and cabotegravir efficacy. (PubMed, Sci China Life Sci) - No abstract available

Journal

HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy. (PubMed, J Antimicrob Chemother) - "These findings demonstrate DTG resistance in both adult and paediatric participants with virological failure with G118R emerging as a prominent resistance pathway. No known primary LEN resistance mutation was detected in the assessable capsid sequences, although phenotypic susceptibility and clinical outcomes were not evaluated. These findings support continued surveillance of integrase and capsid resistance as long-acting antiretroviral strategies expand."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

First Reported Case of Puerperal Immune Reconstitution Inflammatory Syndrome With Multiple Systemic Manifestations in an HIV-Positive Woman: A Case Report and Structured Literature Review. (PubMed, J Int Assoc Provid AIDS Care) - "Concurrent multisystem IRIS, particularly during the puerperium, is extremely rare.Case PresentationWe report a 27-year-old woman newly diagnosed with HIV during the third trimester of pregnancy who initiated dolutegravir-based ART at 35 weeks' gestation...Published literature identified very few cases of three or more simultaneous IRIS events after ART initiation, with no previous reports describing such extensive multisystem involvement in the puerperium.ConclusionThis appears to be the first reported puerperal case of extensive multisystem IRIS. We propose the term "IRIS multiplex" to describe patients presenting with five or more concurrent IRIS manifestations, as a hypothesis-generating concept for future research."

Journal • Review • Candidiasis • Cardiomyopathy • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Pneumonia • Pulmonary Embolism • Respiratory Diseases • Sarcoma • Solid Tumor • Thrombocytopenia